Contrasting Tilray Brands (NASDAQ:TLRY) & Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) and Tilray Brands (NASDAQ:TLRY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Institutional and Insider Ownership

1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Shionogi & Co., Ltd. Unsponsored ADR and Tilray Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shionogi & Co., Ltd. Unsponsored ADR	46.67%	16.13%	12.09%
Tilray Brands	-13.11%	-7.76%	-5.59%

Analyst Ratings

This is a summary of current ratings for Shionogi & Co., Ltd. Unsponsored ADR and Tilray Brands, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shionogi & Co., Ltd. Unsponsored ADR	0	1	0	2	3.33
Tilray Brands	2	2	2	1	2.29

Tilray Brands has a consensus price target of $7.00, indicating a potential upside of 93.91%. Given Tilray Brands’ higher probable upside, analysts plainly believe Tilray Brands is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.

Earnings & Valuation

This table compares Shionogi & Co., Ltd. Unsponsored ADR and Tilray Brands”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shionogi & Co., Ltd. Unsponsored ADR	$3.32 billion	4.51	$1.35 billion	$1.00	8.80
Tilray Brands	$210.48 million	2.34	-$121.40 million	($1.08)	-3.34

Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd. Unsponsored ADR, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.

Summary

Shionogi & Co., Ltd. Unsponsored ADR beats Tilray Brands on 10 of the 15 factors compared between the two stocks.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.